Close Menu

NEW YORK – DermTech reported after the close of the market on Thursday that its fourth quarter revenues rose 31 percent year over year.

For the three months ended Dec. 31, 2020, the La Jolla, California-based developer of genomic melanoma tests posted $2.1 million in revenues, up from $1.6 million in Q4 2019.

Assay revenue soared 220 percent to $1.6 million from $500,000 a year ago. Meanwhile, contract revenue fell 49 percent to about $600,000 million in Q4 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.